Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell TherapiesCaseBioscience® today announced its participation in a multidisciplinary team led by Likarda that has been awarded up to $7.3 million by the Advanced Research Projects Agency for Health (ARPA-H) through its BioStabilization Systems (BoSS)...
- Dianthus Therapeutics, Inc. NEW YORK andDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
- Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded WarrantsSagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to purchase 2,750,010 shares of its Series A common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant. The Pre-Funded Warrants have an exercise price of $0.0001 per share and are exercisable immediately. The gross proceeds from the offering were approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering were sold by Sagimet.
- Clear Scientific, Inc.Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the BodyFentanyl Phase 2 Trial met all endpoints; Phase 3 planned for H1 2027 — Clear Scientific, Inc. today announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that immediately binds and inactivates...
- Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026: Market to Surge to $21.46 Billion by 2030 as Thermo Fisher Scientific, Merck KGaA, Lonza and Samsung Biologics Accelerate AutomationCompanies: Thermo Fisher Scientific Inc.Merck KGaABoost ROI with scalable viral-vector platforms, automated single-use processing, digital quality control, and expanded CDMO capacity through partnerships and acquisitions.
- Continuous Bioprocessing Technologies Market - Global Forecast 2026-2031 | Market to Reach USD 8.5 Billion as Automation and Biologics Demand Fuel 12.1% CAGRBoost ROI through automation, AI, digital twins, modular single-use systems and partnerships that cut costs, improve quality, scale production and speed time to market.
- Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICICandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the publication of final phase 2a clinical trial results (NCT04495153) of aglatimagene besadenovec (aglatimagene) plus valacyclovir in patients with stage III/IV NSCLC who had shown inadequate response to ICI. The trial demonstrated a median overall survival (mOS) of 24.5 months in the evaluable population, substantially exceeding historical benchmarks for standard-of-care docetaxel chemotherapy in this patient population.
- Harmony BiosciencesHarmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy DaysHarmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia. This poster will be presented at the 17th European Narcolepsy Days, taking place October 2–3, 2026, in Bern, Switzerland.
- 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar60 Degrees Pharmaceuticals will release interim severe babesiosis study data and host a KOL investor webinar on October 6, 2026.
- PharmaTher Holdings Ltd.PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing PlatformHighlightsPharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations, consumables, and service.Exclusivity covers every key customer segment: compounding pharmacies (503A and 503B), telehealth and digital health companies, CDMOs, hospitals, academic, research, and government institutions, and pharmaceutical, biotechnology, and healthcare companies.PharmaTher estimates more than 10,000...
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion CapabilitySpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd (Santen) and is the current supplier of SpyGlass Pharma’s IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System.
- Piramal Pharma Solutions y NP2 completan la fase de desarrollo de ciclofosfamida el próximo mesPiramal Pharma Solutions ("PPS"), una organización líder mundial de desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd....